|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1995-7-27
|
|
pubmed:abstractText |
CPT-11 (irinotecan) is a semi-synthetic derivative of camptothecin and exerts its activity by inhibiting DNA topoisomerase I. A phase II study of this drug was performed in patients with pancreatic cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
129-32
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7786820-Adult,
pubmed-meshheading:7786820-Aged,
pubmed-meshheading:7786820-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:7786820-Bone Marrow Diseases,
pubmed-meshheading:7786820-Camptothecin,
pubmed-meshheading:7786820-Disease-Free Survival,
pubmed-meshheading:7786820-Female,
pubmed-meshheading:7786820-Gastrointestinal Diseases,
pubmed-meshheading:7786820-Humans,
pubmed-meshheading:7786820-Infusions, Intravenous,
pubmed-meshheading:7786820-Male,
pubmed-meshheading:7786820-Middle Aged,
pubmed-meshheading:7786820-Pancreatic Neoplasms,
pubmed-meshheading:7786820-Remission Induction,
pubmed-meshheading:7786820-Topoisomerase I Inhibitors,
pubmed-meshheading:7786820-Treatment Outcome
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study.
|
|
pubmed:affiliation |
Department of Medical Oncology, University Hospital Nijmegen, The Netherlands.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
